Princeton Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.49M | Buy |
14,531
+22
| +0.2% | +$10.3K | 1.77% | 11 |
|
|
2025
Q4 | $6.58M | Buy |
14,509
+71
| +0.5% | +$30.6K | 1.7% | 11 |
|
|
2025
Q3 | $5.65M | Sell |
14,438
-37
| -0.3% | -$15.5K | 1.52% | 15 |
|
|
2025
Q2 | $6.44M | Sell |
14,475
-561
| -4% | -$259K | 1.91% | 11 |
|
|
2025
Q1 | $7.29M | Sell |
15,036
-138
| -0.9% | -$64.3K | 2.57% | 8 |
|
|
2024
Q4 | $6.11M | Buy |
15,174
+64
| +0.4% | +$29.7K | 1.89% | 11 |
|
|
2024
Q3 | $7.03M | Buy |
15,110
+74
| +0.5% | +$35.5K | 2.21% | 11 |
|
|
2024
Q2 | $7.05M | Sell |
15,036
-193
| -1% | -$83.8K | 2.3% | 9 |
|
|
2024
Q1 | $6.37M | Sell |
15,229
-66
| -0.4% | -$27.9K | 2.3% | 9 |
|
|
2023
Q4 | $6.22M | Sell |
15,295
-73
| -0.5% | -$27K | 2.51% | 10 |
|
|
2023
Q3 | $5.34M | Sell |
15,368
-205
| -1% | -$71.7K | 2.46% | 9 |
|
|
2023
Q2 | $5.48M | Buy |
15,573
+198
| +1% | +$66.7K | 2.28% | 8 |
|
|
2023
Q1 | $4.84M | Sell |
15,375
-720
| -4% | -$216K | 2.07% | 13 |
|
|
2022
Q4 | $4.65M | Sell |
16,095
-164
| -1% | -$50K | 2.07% | 14 |
|
|
2022
Q3 | $4.71M | Buy |
16,259
+297
| +2% | +$85.5K | 2.06% | 14 |
|
|
2022
Q2 | $4.5M | Sell |
15,962
-451
| -3% | -$121K | 1.74% | 15 |
|
|
2022
Q1 | $4.28M | Sell |
16,413
-168
| -1% | -$39.9K | 1.33% | 20 |
|
|
2021
Q4 | $3.64M | Sell |
16,581
-510
| -3% | -$99.2K | 1.04% | 29 |
|
|
2021
Q3 | $3.1M | Buy |
17,091
+156
| +0.9% | +$30.5K | 0.99% | 33 |
|
|
2021
Q2 | $3.42M | Buy |
16,935
+223
| +1% | +$46.6K | 1.06% | 30 |
|
|
2021
Q1 | $3.59M | Buy |
16,712
+322
| +2% | +$70.7K | 1.21% | 28 |
|
|
2020
Q4 | $3.87M | Sell |
16,390
-656
| -4% | -$151K | 1.39% | 23 |
|
|
2020
Q3 | $4.64M | Buy |
17,046
+195
| +1% | +$53.8K | 1.87% | 17 |
|
|
2020
Q2 | $4.89M | Buy |
16,851
+1,296
| +8% | +$351K | 2.17% | 14 |
|
|
2020
Q1 | $4.2M | Sell |
15,555
-2,238
| -13% | -$513K | 2.18% | 15 |
|
|
2019
Q4 | $4.27M | Sell |
17,793
-97
| -0.5% | -$19.6K | 1.91% | 17 |
|
|
2019
Q3 | $3.03M | Buy |
17,890
+106
| +0.6% | +$18.8K | 1.47% | 23 |
|
|
2019
Q2 | $3.26M | Buy |
17,784
+359
| +2% | +$62.8K | 1.59% | 21 |
|
|
2019
Q1 | $3.21M | Sell |
17,425
-605
| -3% | -$112K | 1.62% | 22 |
|
|
2018
Q4 | $2.99M | Sell |
18,030
-1,009
| -5% | -$175K | 1.74% | 21 |
|
|
2018
Q3 | $3.67M | Sell |
19,039
-350
| -2% | -$62.3K | 1.52% | 25 |
|
|
2018
Q2 | $3.29M | Sell |
19,389
-166
| -0.8% | -$25.7K | 1.43% | 25 |
|
|
2018
Q1 | $3.19M | Sell |
19,555
-831
| -4% | -$136K | 1.42% | 25 |
|
|
2017
Q4 | $3.06M | Buy |
+20,386
| New | +$3.02M | 1.37% | 26 |
|
Other funds holding VRTX
VCM
VPM
Princeton Capital Management's VRTX Position: Q1 2026 in Review
Princeton Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.15% in Q1 2026, buying an estimated $10.3K and bringing the position to 14,531 shares worth $6.49M. The position accounts for 1.77% of the portfolio, ranked #11.
Princeton Capital Management first reported a position in VRTX in Q4 2017 and has held it in 34 quarters since. The position peaked at $7.29M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Princeton Capital Management held 14,531 shares of Vertex Pharmaceuticals worth $6.49M as of Q1 2026.
- Princeton Capital Management bought 22 Vertex Pharmaceuticals shares in Q1 2026, an estimated $10.3K.
- Vertex Pharmaceuticals made up 1.77% of Princeton Capital Management's portfolio in Q1 2026, its #11 holding.
- Princeton Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Princeton Capital Management's Vertex Pharmaceuticals position peaked at $7.29M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Princeton Capital Management's 13F filing for Q1 2026, filed 8 May 2026.